Browse Publications
-
Living LegendAlice Thomas: Walking a Non-Traditional Path
At 79 years old, Alice Thomas is definitely not your traditional law student, but all her life she’s walked a fairly non-traditional path. Leaving home at just 16 years old, Thomas worked a variety of jobs to support herself including a drug-store waitress, a typist, and even an elevator operator. She eventually found herself in the construction industry despite the fact that it was and continues to be a “man’s world.” -
Science in the SpotlightAll Roads Lead to...Sardinia!?
A drug now in clinical trials for treatment of type 2 diabetes could eventually be used to promote longevity by treating or preventing major age-related diseases. -
Document, TestimonyAlliance Calls for Increased NIH Appropriations in FY 2014
On March 15, 2013, the Alliance for Aging Research submitted testimony to the House Appropriations, Labor, Health and Human Services, and Education Subcommittee, calling for $32 billion in funding for the National Institutes of Health (NIH) in FY 2014. To justify this increase, the Alliance highlighted important NIH-supported work administered through the National Institute on Aging (NIA) and other of the NIH's 27 Institutes and Centers. Particular attention was paid to advances in understanding the basic biology of aging and its link to chronic disease and the formation of a Geroscience Interest Group (GSIG) comprised of 20 Institutes and Centers to coordinate discussion and action across the NIH on research into the processes of aging that underpin most major age-related disease.
To read the Alliance's testimony, click here.
-
Document, TestimonyAlliance President Makes Remarks at a Hearing on Prescription Drug User Fee Act Reauthorization
On April 12th, Alliance President & CEO Daniel Perry presented remarks at a public meeting on the reauthorization process for the Prescription Drug User Fee Act (PDUFA). PDUFA IV, currently set to expire in September of 2012, authorizes the Food and Drug Administration (FDA) to collect user fees from companies wishing to submit their products for agency review. The intention is that the fees would be used to provide an additional revenue stream for FDA to hire more staff, improve systems, and establish a better managed drug review process to speed up the delivery of needed therapies to the public. -
Document, TestimonyAlliance President Makes Remarks at a Hearing on Prescription Drug User Fee Act Reauthorization
On October 24th, Alliance President & CEO Daniel Perry presented remarks at a public meeting on the fifth reauthorization of the Prescription Drug User Fee Act (PDUFA). PDUFA IV, currently set to expire in September of 2012, authorizes the Food and Drug Administration (FDA) to collect user fees from companies wishing to submit their products for agency review. The intention is that the fees would be used to provide an additional revenue stream for FDA to hire more staff, improve systems, and establish a better managed drug review process to speed up the delivery of needed therapies to the public. The PDUFA reauthorization process has historically been conducted through negotiations between the Agency and regulated industries, however the current round of negotiations allowed for patient groups to engage in monthly consultations with FDA representatives to enable all stakeholders to have an early voice in shaping the PDUFA V agreement.